Pharmacogenomics of antidepressant treatment effects

Julio Licinio, Ma-Li Wong, Julio Licinio, Ma-Li Wong

Abstract

There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.

Figures

Figure 1.. CYP2D6-mediated quantitative influences on pharmacokinetics…
Figure 1.. CYP2D6-mediated quantitative influences on pharmacokinetics of antidepressant drugs expressed as percent dose adjustments: CYP2D6 poor metabolizers (PM, white), intermediate metabolizers (IM, gray), extensive metabolizers (EM, dark gray), ultrarapid metabolizers (UM, black) Dose adjustments were calculated according to the data given in Table II. If data on active drug moiety (consisting on active principle metaboite+parent drug of active enantiomers of a racemic drug) were given, dose recommendations were based on these data only (other studies not providing so detailed information were not incorporated). If more than one study was integrated, the weighted mean for the dose adjustment was taken according to the number of poor metabolizers in each study. Data on mirtazapine, moclobemide, fluoxetine, and maprotiline were not shown in the figure, since no dose adjustment based on CYP2D6 can be recommended at present. Reproduced from ref 43: Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. Copyright © Nature Publishing Group 2004
Figure 2.. CYP2C19-mediated quantitative influences on pharmacokinetics…
Figure 2.. CYP2C19-mediated quantitative influences on pharmacokinetics of antidepressant drugs expressed as percentage dose adaptations: CYP2C19 poor metabolizers (PM, white), intermediate metabolizers (IM, gray), extensive metabolizers (EM, dark gray). Reproduced from ref 43: Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. Copyright © Nature Publishing Group 2004

References

    1. Lesko LJ., Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov. 2004;3:763–769.
    1. Dokoumetzidis A., Karalis V., Iliadis A., Macheras P. The heterogeneous course of drug transit through the body. Trends Pharmacol Sci. 2004;25:140–146.
    1. Lesch KP., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527–1531.
    1. Nakamura M., Ueno S., Sano A., Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry. 2000;5:32–38.
    1. Kraft JB., Slager SL., McGrath PJ., Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005;58:374–381.
    1. Hu X., Oroszi G., Chun J., Smith TL., Goldman D., Schuckit MA. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res. 2005;29:8–16.
    1. Wendland JR., Martin BJ., Kruse MR., Lesch KP., Murphy DL. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry. 2006;11:224–226.
    1. Willeit M., Praschak-Rieder N. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage. 2010;53:878–892.
    1. Hertting G., Axelrod J. Fate of tritiated noradrenaline at the sympathetic nerve-endings. Nature. 1961;192:172–173.
    1. Hertting G., Axelrod J., Kopin IJ., Whitby LG. Lack of uptake of catecholamines after chronic denervation of sympathetic nerves. Nature. 1961;189:66.
    1. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508–511.
    1. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247–257.
    1. Horstmann S., Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009;124:57–73.
    1. Porcelli S., Drago A., Fabbri C., Gibiino S., Calati R., Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011;36:87–113.
    1. Kang RH., Wong ML., Chol MJ., Paik JW., Lee MS. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1317–1321.
    1. Kim DK., Lim SW., Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11:215–219.
    1. Yoshida K., Ito K., Sato K., et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:383–386.
    1. Kim H., Lim SW., Kim S., et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006;296:1609–1618.
    1. Yoshida K., Takahashi H., Higuchi H., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161:1575–1580.
    1. Yoshimura R., Umene-Nakano W., Suzuki A., et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009;24:489–494.
    1. Yu YW., Tsai SJ., Chen TJ., Lin CH., Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002;7:1115–1119.
    1. Lee MS., Lee HY., Lee HJ., Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet. 2004;14:111–115.
    1. Kato M., Ikenaga Y., Wakeno M., et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol. 2005;20:151–156.
    1. Min W., Li T., Ma X., Li Z., Yu T., Gao D., et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl). 2009;205:409–417.
    1. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473–500.
    1. Kato M., Fukuda T., Wakeno M., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology . 2006;53:186–195.
    1. Kirchheiner J., Nickchen K., Sasse J., Bauer M., Roots I., Brockmoller J. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J. 2007;7:48–55.
    1. Pae CU., Mandelli L., Serretti A., et al. Heat-shock protein-70 genes and response to antidepressants in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1006–1011.
    1. Gau YT., Liou YJ., Yu YW., et al. Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:594–599.
    1. Tadic A., Rujescu D., Muller MJ., et al. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1370–1377.
    1. Papiol S., Arias B., Gasto C., Gutierrez B., Catalan R., Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104:83–90.
    1. Tsai SJ., Liou YJ., Hong CJ., Yu YW., Chen TJ. Glycogen synthase kinase3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J. 2008;8:384–390.
    1. Perlis RH., Moorjani P., Fagerness J., et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology. 2008;33:2810–19.
    1. Tsai SJ., Hong CJ., Liou YJ., Yu YW., Chen TJ. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics. 2008;18:869–875.
    1. Wakeno M., Kato M., Okugawa G., et al. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol. 2008;28:518–524.
    1. Domschke K., Dannlowski U., Ohrmann P., et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol. 2008;18:751–759.
    1. Wong ML., Dong C., Maestre-Mesa J., Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry. 2008;13:800–812.
    1. Uhr M., Tontsch A., Namendorf C., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203–209.
    1. Roberts RL., Joyce PR., Mulder RT., Begg EJ., Kennedy MA. A common Pglycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2:191–196.
    1. Laika B., Leucht S., Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem. 2006;52:893–895.
    1. Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther. 2007;82:606–609.
    1. Tomalik-Scharte D., Lazar A., Fuhr U., Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 2008;8:4–15.
    1. Kirchheiner J., Nickchen K., Bauer M., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442–473.
    1. XX Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9:819–25.
    1. Mervis J. U.S. science policy. The battle over the 201 1 budget: what's at stake for research. Science. 2011;331:14–15.
    1. Collins F. The bridge between lab and clinic. Interview by Meredith Wadman. Nature. 2010:468–877.
    1. Licinio J., Wong ML. The pharmacogenomics of depression. Pharmacogenomics J. 2001;1:175–177.
    1. Licinio J., Alvarado I., Wong ML. Will pharmacogenomics guide clinical practice? Pharmacogenomics J. 2002;2
    1. Licinio J. Pharmacogenomics and clinical medicine: passing flirtation or marriage? Pharmacogenomics J . 2003;3
    1. Licinio J., Wong ML. Pharmacogenomics in psychiatry: clinical issues to be considered. Mol Psychiatry. 2005;10
    1. Licinio J., Wong ML. Pharmacogenomics in psychiatry: genomic considerations. Mol Psychiatry. 2005;10
    1. Licinio J., Wong ML. Pharmacogenomics of antidepressants: what is next? Mol Psychiatry. 2010;15
    1. Esposito K., Reierson GW., Luo HR., Wu GS., Licinio J., Wong ML. Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med. 2009;41:177–185.
    1. Wong ML., Whelan F., Deloukas P., et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A. 2006;103:15124–129.
    1. Licinio J., O'Kirwan F., Irizarry K., et al. Association of a corticotropinreleasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9:1075–1082.
    1. Collins FS. Research agenda. Opportunities for research and NIH. Science. 2010;327:36–37.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever